伊朗草药 Zofa® 糖浆治疗 COVID-19 患者临床症状的效果:随机临床试验。

IF 1.9 Q3 CHEMISTRY, MEDICINAL
Ali Ghazvini, Amir Vahedian-Azimi, Morteza Abdoli, Farshid Rahimibashar, Yunes Panahi, Thozhukat Sathyapalan, Amirhossein Sahebkar
{"title":"伊朗草药 Zofa® 糖浆治疗 COVID-19 患者临床症状的效果:随机临床试验。","authors":"Ali Ghazvini, Amir Vahedian-Azimi, Morteza Abdoli, Farshid Rahimibashar, Yunes Panahi, Thozhukat Sathyapalan, Amirhossein Sahebkar","doi":"10.22038/AJP.2023.21909","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to determine the role of Iranian herbal Zofa<sup>®</sup> syrup in improving the clinical symptoms of patients with COVID-19.</p><p><strong>Materials and methods: </strong>This randomized clinical trial was conducted on 105 patients with COVID-19. Patients were randomly assigned to the intervention (n=35) group (received 10 ml of Zofa<sup>®</sup> syrup every 8 hours/seven days plus standard treatment) or the control (n=70) group (received only standard treatment). Assessments were performed before and after treatment.</p><p><strong>Results: </strong>The groups were comparable regarding age (p=0.980), gender (p=0.584), comorbidities (p=0.318), or drug history (p=0.771). There was no difference between patients' recovery status at the time of discharge (p=0.327) or two weeks post-discharge (p=0.165) in the intervention and control groups. No patient was hospitalized to the intensive care unit (ICU) for supplemental oxygen therapy and no patient died in the intervention group. However, in the control group, three (4.5%) patients were transferred to the ICU, and two (3.03%) patients died.</p><p><strong>Conclusion: </strong>Considering the better recovery status of the patients at the time of discharge and the absence of patient deaths in the intervention group, more additional studies are needed to confirm these findings and elucidate the role of Zofa<sup>®</sup> in COVID-19.</p>","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711577/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Iranian herbal Zofa<sup>®</sup> syrup for the management of clinical symptoms in patients with COVID-19: A randomized clinical trial.\",\"authors\":\"Ali Ghazvini, Amir Vahedian-Azimi, Morteza Abdoli, Farshid Rahimibashar, Yunes Panahi, Thozhukat Sathyapalan, Amirhossein Sahebkar\",\"doi\":\"10.22038/AJP.2023.21909\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The objective of this study was to determine the role of Iranian herbal Zofa<sup>®</sup> syrup in improving the clinical symptoms of patients with COVID-19.</p><p><strong>Materials and methods: </strong>This randomized clinical trial was conducted on 105 patients with COVID-19. Patients were randomly assigned to the intervention (n=35) group (received 10 ml of Zofa<sup>®</sup> syrup every 8 hours/seven days plus standard treatment) or the control (n=70) group (received only standard treatment). Assessments were performed before and after treatment.</p><p><strong>Results: </strong>The groups were comparable regarding age (p=0.980), gender (p=0.584), comorbidities (p=0.318), or drug history (p=0.771). There was no difference between patients' recovery status at the time of discharge (p=0.327) or two weeks post-discharge (p=0.165) in the intervention and control groups. No patient was hospitalized to the intensive care unit (ICU) for supplemental oxygen therapy and no patient died in the intervention group. However, in the control group, three (4.5%) patients were transferred to the ICU, and two (3.03%) patients died.</p><p><strong>Conclusion: </strong>Considering the better recovery status of the patients at the time of discharge and the absence of patient deaths in the intervention group, more additional studies are needed to confirm these findings and elucidate the role of Zofa<sup>®</sup> in COVID-19.</p>\",\"PeriodicalId\":8677,\"journal\":{\"name\":\"Avicenna Journal of Phytomedicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711577/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Avicenna Journal of Phytomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22038/AJP.2023.21909\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2023.21909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究旨在确定伊朗草药 Zofa® 糖浆在改善 COVID-19 患者临床症状方面的作用:本随机临床试验针对 105 名 COVID-19 患者。患者被随机分配到干预组(n=35)(每8小时/7天服用10毫升Zofa®糖浆,并接受标准治疗)或对照组(n=70)(仅接受标准治疗)。治疗前后进行了评估:两组患者在年龄(P=0.980)、性别(P=0.584)、合并症(P=0.318)或用药史(P=0.771)方面具有可比性。干预组和对照组患者在出院时(p=0.327)或出院后两周(p=0.165)的康复状况没有差异。在干预组中,没有患者因补充氧气治疗而住进重症监护室(ICU),也没有患者死亡。然而,在对照组中,有三名患者(4.5%)转入重症监护室,两名患者(3.03%)死亡:考虑到干预组患者出院时的恢复情况较好,而且没有患者死亡,因此需要更多的研究来证实这些发现,并阐明 Zofa® 在 COVID-19 中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of Iranian herbal Zofa® syrup for the management of clinical symptoms in patients with COVID-19: A randomized clinical trial.

Objective: The objective of this study was to determine the role of Iranian herbal Zofa® syrup in improving the clinical symptoms of patients with COVID-19.

Materials and methods: This randomized clinical trial was conducted on 105 patients with COVID-19. Patients were randomly assigned to the intervention (n=35) group (received 10 ml of Zofa® syrup every 8 hours/seven days plus standard treatment) or the control (n=70) group (received only standard treatment). Assessments were performed before and after treatment.

Results: The groups were comparable regarding age (p=0.980), gender (p=0.584), comorbidities (p=0.318), or drug history (p=0.771). There was no difference between patients' recovery status at the time of discharge (p=0.327) or two weeks post-discharge (p=0.165) in the intervention and control groups. No patient was hospitalized to the intensive care unit (ICU) for supplemental oxygen therapy and no patient died in the intervention group. However, in the control group, three (4.5%) patients were transferred to the ICU, and two (3.03%) patients died.

Conclusion: Considering the better recovery status of the patients at the time of discharge and the absence of patient deaths in the intervention group, more additional studies are needed to confirm these findings and elucidate the role of Zofa® in COVID-19.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Avicenna Journal of Phytomedicine
Avicenna Journal of Phytomedicine CHEMISTRY, MEDICINAL-
CiteScore
3.40
自引率
4.50%
发文量
17
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信